Mebendazole Shortage: What Providers and Prescribers Need to Know in 2026

Mebendazole (brand name: Emverm) holds a unique position in the US anthelmintic landscape: it is not formally listed on the FDA Drug Shortage Database, yet it remains difficult for many patients to access due to the absence of a generic equivalent and a retail price that often exceeds $4,000 for a standard treatment course. For prescribers managing patients with intestinal helminth infections, understanding the current market dynamics and available clinical alternatives is essential to ensuring continuity of care.

The Current Mebendazole Market: What Prescribers Need to Understand

As of 2026, the only commercially available form of mebendazole in the United States is Emverm 100 mg chewable tablets, manufactured by Amneal Pharmaceuticals. The previous US brand (Vermox) was discontinued around 2011, and no FDA-approved generic mebendazole is currently on the US market. This situation is the result of market forces typical of niche medications: low US demand relative to manufacturing costs, combined with limited competitive pressure, has enabled sustained high pricing.

The retail price of Emverm typically ranges from $4,287 to over $5,258 for just 2 tablets — the quantity prescribed for pinworm. For a three-day course (6 tablets for roundworm, hookworm, or whipworm), cost can be substantially higher. This pricing creates real-world barriers for patients even when coverage technically exists, since formulary placement and prior authorization requirements vary widely across payers.

Clinical Summary: Mebendazole Indications and Dosing

Mebendazole (Emverm) is FDA-approved for the treatment of patients aged 2 years and older with gastrointestinal infections caused by:

• Enterobius vermicularis (pinworm): 100 mg single oral dose; second dose recommended after 3 weeks
• Ascaris lumbricoides (roundworm): 100 mg twice daily for 3 consecutive days
• Ancylostoma duodenale / Necator americanus (hookworm): 100 mg twice daily for 3 consecutive days
• Trichuris trichiura (whipworm): 100 mg twice daily for 3 consecutive days

Off-label uses include capillariasis, toxocariasis, trichinellosis (Trichinella spiralis), cystic echinococcosis (Echinococcus granulosus), and trichostrongyliasis. For systemic infections (echinococcosis, toxocariasis), albendazole is generally preferred given its superior systemic absorption.

Key Drug Interactions and Contraindications

Before prescribing mebendazole, be aware of the following clinically significant interactions and contraindications:

• Metronidazole (Contraindicated): Concurrent use may trigger Stevens-Johnson syndrome or toxic epidermal necrolysis. This combination should be avoided.
• Phenytoin / Fosphenytoin / Carbamazepine: These anticonvulsants significantly reduce serum mebendazole levels by inducing CYP450-mediated metabolism, potentially reducing efficacy.
• Deferiprone / Ropeginterferon alfa-2b: Additive myelosuppression risk; avoid combination and monitor absolute neutrophil count if unavoidable.
• Contraindicated under age 1: Convulsions have been reported in post-marketing experience with mebendazole in infants under 1 year. Use in children under 2 years requires careful consideration.
• Pregnancy (Category C): Avoid in the first trimester. Data suggest no increased congenital anomalies with use in the second or third trimester during mass drug administration campaigns, but use only if benefits outweigh risks.
• Hepatic impairment: Use with caution; mebendazole is metabolized by the CYP450 system. Periodic hepatic function monitoring is advisable with prolonged therapy.

Clinical Alternatives for When Mebendazole Is Unavailable or Unaffordable

For each indication, the following alternatives may be appropriate:

• Enterobiasis (pinworm): Pyrantel pamoate 11 mg/kg as single dose (OTC, $8–$15) or albendazole 400 mg single dose (generic available, $37–$150 with discount). Treat all household members simultaneously.
• Ascariasis (roundworm): Albendazole 400 mg single dose or daily for 3 days; ivermectin is effective for Ascaris as an alternative.
• Hookworm (Ancylostoma/Necator): Albendazole 400 mg once daily for 3 days; pyrantel pamoate (OTC) for uncomplicated cases. Consider iron supplementation if anemia is present.
• Trichuriasis (whipworm): Albendazole 400 mg once daily for 3 days. Note that single-dose mebendazole 500 mg has shown superior efficacy vs. single-dose albendazole 400 mg for T. trichiura in some studies; multi-day dosing with albendazole is preferred if mebendazole is unavailable.

Helping Your Patients Navigate Cost Barriers

If you plan to prescribe mebendazole (Emverm), proactively connecting your patients with the manufacturer savings program can dramatically reduce their financial burden:

• Emverm Savings Program (Amneal Pharmaceuticals): Eligible commercially insured patients can pay as little as $5 per fill (max savings $80 per script, up to 12 uses). Website: emverm.com/savings-program | Phone: 1-877-264-2440.
• Prior authorization support: For commercially insured patients who require prior authorization, your practice team can submit documentation of the specific parasitic infection diagnosis (confirmed by stool studies or clinical findings) to support approval.

Checking Pharmacy Availability Before Writing the Prescription

Not all pharmacies routinely stock Emverm. Before sending a prescription, consider verifying availability. medfinder for providers is a service that calls pharmacies near your patient to identify which ones have the medication in stock — saving your patient the frustration of showing up at a pharmacy that can't fill the prescription.

Independent community pharmacies and hospital outpatient pharmacies are generally more likely to carry or be able to order specialty antiparasitic medications like Emverm compared to large chain pharmacies.

Summary Recommendations for Prescribers

1. Verify pharmacy stock before writing the prescription to prevent patient frustration.
2. Provide all commercially insured patients with information about the Emverm Savings Program ($5/fill minimum).
3. For uninsured or government-insured patients where cost is a barrier, consider albendazole (with generic available) or pyrantel pamoate OTC (for pinworm/hookworm) as first-line alternatives.
4. Screen for drug interactions, especially metronidazole co-prescription and anticonvulsant use (phenytoin, carbamazepine) which significantly reduce mebendazole efficacy.
5. Treat all household members simultaneously for pinworm to prevent reinfection cycles.